Health
June 5, 2024
How would you describe Deemea?
Deemea is a PharmaTech that has developed a unique software suite based on AI foundation models for scalable multi-site access, collection, interpretation and prediction on medical imaging data. This eClinical solution addresses the needs of clinicians, CROs, bio-pharmaceutical and medical devices companies by providing fast, compliant, reliable and cost-effective RWE and trial analytics.
Deemea is strategically positioned at the intersection of AI and medical imaging, enhancing the value of the locally stored imaging exams in clinical centers. This capability meets the needs of various stakeholders: from ensuring medical quality control in routine clinical settings, to providing analytics for clinical trials that rely on medical imaging as critical endpoints, or enabling precision medicine thanks to co-development of novel biomarkers or opportunistic pre-screening.
What motivated your investment?
1. An expert team led by Charlotte Pouchy, PhD (CEO) having a background in clinical research (at GSK, then INSERM) as well as in the development of AI-based applications for medical imaging (at Therapixel, then Incepto). Other members of the team come from leading clinical centers or healthcare software development companies. And all bring great insights on the needs of the target customers of Deemea.
2. Breakthrough technologies to answer the needs of Deemea’s customers:
a. Serena: an AI-integrated Research PACS based on a universal API for multi-source data collection and aggregation, utilizing imaging modality AI foundation models for data quality control and indexing. It ensures confidentiality and sovereignty, supporting robust data management and secure workflows.
b. Harmony: An AI-powered imaging viewer enhanced by an expanding library of proprietary AI algorithms, open-source, and partnered applications for the analytics of images specific to clinical situations. Today the company is already serving the needs of a variety of users in orthopedics, rheumatology, oncology, neurology and several rare diseases.
A highly relevant positioning validated by initial landmark collaborations, and benefitting from a network multiplier effect: the technology is currently being deployed in 12 centers across 4 countries. 16 additional centers will be live by end 2024, offering an urivaled access to RWD scalarly. Also the company has demonstrated a rapid ability to generate revenue, as its product address an immediate and pressing need within R&D of Biopharmaceutical and Medical Devices industries.
3. A white-hot PharmaTech market with strong demand globally from CROs, biopharmaceutical and medical device companies for thin capillarity RWD access as well as novel scalable and reliable analytics solution, with aim at accelerating and providing sizeable savings of multi-centric clinical trials.
How does this investment fit in with Karista's philosophy?
PharmaTech is a target category of Karista, investing in modern tools for the most strategic processes of the biopharmaceutical and medical device industries: clinical development and post-market surveillance.
Deemea has already demonstrated its ability to meet the needs of these demanding customers, and deploy a scalable and solvable business model.
Besides the overall growth of the sector, we see the first landmark M&A in this category, with different types of acquisitive majors.
In addition, with this investment, we can also meet our ambition for non-financial returns, enabling better care (precision medicine is an example amongst others), lowering the cost of developing medical products (thus their final cost), and accelerating their availability for clinical use, as well as spreading modern tools and data to researchers at scale.
